2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Breast Neoplasms
4
Pain, Postoperative
3
Spondylitis, Ankylosing
2
Pain
2
Neoplasms
2
Lung Neoplasms
2
Colonic Neoplasms
2
Agnosia
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sexual Dysfunction, Physiological
1
Pituitary Neoplasms
1
Ovarian Neoplasms
1
Neoplasm, Residual
1
Mucositis
1
Lymphoma, Follicular
1
Inflammation
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Chronic Pain
1
Carcinoma, Non-Small-Cell Lung
1
Arthritis, Rheumatoid
1
Arthritis, Psoriatic
1
Anastomotic Leak
1
Adenocarcinoma of Lung
1
Acute Pain
1
Interventions
Cisplatin
281
pembrolizumab
234
Radiotherapy
171
Cetuximab
169
Carboplatin
123
Docetaxel
110
Paclitaxel
96
Fluorouracil
95
Nivolumab
88
Radiotherapy, Intensity-Modulated
80
Magnetic Resonance Spectroscopy
39
durvalumab
36
Radiation
33
Surgical Procedures, Operative
32
Drug Therapy
32
Biopsy
28
Radiosurgery
25
Erlotinib Hydrochloride
25
Albumin-Bound Paclitaxel
24
130-nm albumin-bound paclitaxel
24
Taxes
23
Specimen Handling
22
Platinum
22
Immunohistochemistry
21
tislelizumab
20
1,2-diaminocyclohexaneplatinum II citrate
20
Cyclophosphamide
19
Chemoradiotherapy
19
Capecitabine
19
tremelimumab
18
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Squamous Cell Carcinoma of Head and Neck
×
Anti-Inflammatory Agents, Non-Steroidal
×
Clear all
NCT02609386
2024-01-30
INSPIRE
Brooklyn ImmunoTherapeutics, LLC
Phase 2
Completed
105 enrolled
17 charts